UNSPSC 51434910: Amlodipine/telmisartan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434910 Amlodipine/telmisartan is a Commodity code covering specific combination antihypertensive pharmaceuticals and related medications purchased by state and local health agencies, emergency services, and pharmacy benefit programs. State and local governments procure these drugs primarily for emergency medical services (EMS) and fire rescue operations, pharmacy benefit programs, and multi-state cooperative purchasing networks serving state facilities and Medicaid programs. The scope includes branded and generic formulations meeting FDA requirements, cGMP certification, and Drug Supply Chain Security Act (DSCSA) compliance, with vendors required to maintain expiration dates of at least one year from manufacture and to supply comprehensive Safety Data Sheets and product accessibility documentation. Issuing bodies include municipal fire and rescue departments (such as Tampa Fire Rescue), state health and human services agencies and their pharmacy benefit divisions (such as Texas HHS Commission), and multi-state cooperative purchasing alliances serving state governments and local facilities (such as Minnesota Multistate Cooperative Purchasing Alliance).

Recent activity spans Florida, Texas, and Minnesota-coordinated multi-state purchasing. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with four specific medication line items (Labetalol, Epinephrine, Adenosine, and Diltiazem) with a contract value of $40,000 and a response deadline of April 8, 2026; this procurement included a 5 percent bid discount for Small Local Business Enterprise participation and required delivery within ten calendar days of order. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization arrangements, signaling exploratory procurement ahead of a formal RFP. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products to supply participating state and local facilities across Minnesota and Oregon, with proposals due March 26, 2026 and awarded vendors to be available to authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) by May 15, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain contractual relationships with at least two of three authorized wholesalers.